ENTRx is a biotech company that develops therapeutics targeted for human and veterinary ear diseases.
The company was founded by a practicing ENT and a pharmacist. ENTRx’s patented technology is a gel-like viscous suspension used to fill the ear canal, ensuring contact with all infected tissue.
OTITIS EXTERNA: AN IMPRECISE DIAGNOSIS
“Here is a good old-fashioned acute otitis externa. Is it fungus? Is it bacteria? Both? You’ll never know until they fail treatment and weeks have gone by.”
Matthew Branch, M.D.
CEO and Co-founder, ENTRx
OTITIS EXTERNA: ORIGINS
OTITIS EXTERNA: EPIDEMIOLOGY
One in 10 patients will suffer otitis externa in a lifetime.
90% of cases of otitis externa are due to bacteria.
10 % of otitis externa are due to fungus.
Fungal otitis externa is more common when a patient has already been treated with antibiotic drops and when symptoms last longer than one week.
BACTERIA OR FUNGUS:
WHY IS OTITIS EXTERNA HARD TO TREAT?
A Diagnosis of Guesswork
Co-pathogens: Bacterial, fungal, or mixed
NOT standard of care to culture on the first visit
Fungus RARELY diagnosed until therapy fails -- often WEEKS after initial symptoms
Visually difficult to differentiate infections
Clogged and Swollen Canals:
A plumbing problem
No continuous contact with the infected tissue
Sparse and inconsistent coverage
Rapid egress from the ear canal
Subtherapeutic concentrations in the microenvironment
Drops Drip Out
Edema, bacterial pus, waxy debris, and fungal mass
Difficult drop delivery
TREATMENT CHALLENGES
Initial encounter rarely yields correct diagnosis of fungus
No FDA-approved treatment for fungus in the ear
Off-label treatments not ideal, often requiring repeat office visits to debride excipients from canal
Development of fungal otitis externa as a secondary infection
Is It Fungus?
Hard to aim drops into clogged and swollen canal
Difficult for older patients with poor dexterity
Tedious: self-administered fourteen times over one week
Patients rarely use drops as prescribed
Poor Patient Compliance
Home
Office
OUR LEADERSHIP
Pam Randhawa, MPM
Advisor
Pam Randhawa is CEO and Founder of Empiriko, an early-stage biotech company focused on developing antiviral therapeutics and home/clinic-based point-of-care diagnostics for personalized patient treatment and monitoring. Pam has over 20 years of leadership experience in the healthcare/life sciences industries. Prior to founding Empiriko, she co-founded AgroGreen Biofuels, an alternative biofuels technology company using agriculture waste.
Pam serves on the Board of Directors of the Massachusetts Life Sciences Center (MLSC), a state investment agency responsible for $1.6 billion fund to support life sciences innovation. She is the Chair of the Board of Directors of the Massachusetts Biotechnology Council. Pam also serves on the Board of Directors of Hercules Capital with $15 billion under management.
Pam has served on several boards and councils, including the World Economic Forum’s Global Future Council on Biotechnology; the NSF/NIJ Industrial Advisory Board of Center for Advanced Research in Forensic Science chair; the NIH review panel for SBIR/STTR Commercialization Readiness Pilot Program, the Economic Development Planning Council for the State of MA and the Women’s Workforce Council to eliminate the gender wage gap. She serves as a judge for the Harvard Business School’s New Venture Competition. Pam holds a bachelor’s degree in economics from the University of Rajasthan, India, and earned a master’s degree from the Heinz School of Public Policy and Management at Carnegie-Mellon University.
Matthew Branch, M.D.
Chief Executive Officer & Co-founder
Matthew Branch, M.D. is a board-certified otolaryngologist-head and neck surgeon. He has a private practice in Waxahachie, Texas. Matt is an active member of the American Academy of Otolaryngology-Head and Neck Surgery and the Texas Medical Association.
Matt has also published scientific papers, book chapters, and professional presentations in the areas of otology, skull-base surgery, head and neck cancer surgery, and wound healing. As a general otolaryngologist serving nine counties, he leveraged 18 years of clinical expertise to develop a technology that expedites the treatment of otitis externa. Matt co- founded ENTRx in 2011.
Originally from Texas, Matt attended the University of Texas HSC Medical School in Houston, Texas. Matt is a graduate of the University of Pittsburgh Medical Center’s prestigious otolaryngology residency program.
Vance Oglesbee, RPh.
Chief Operating Officer & Co-founder
Vance is a formulation pharmacist and an entrepreneur in the prescription compounding space. As CEO of Hometown Pharmacy, Vance owns and operates three pharmacies in Texas.
Over the years, he has advised on pharmacy chain management and the purchase and sale of pharmacies. Vance is a current director and past Chairman of American Pharmacies, a large national independent pharmacy cooperative.
Vance leveraged his background in prescription compounding to develop a proprietary technology to expedite the treatment of otitis externa. Vance co-founded ENTRx in 2011.
He currently serves as Vice President of the Freestone Medical Center Board of Directors. Vance also co-owns and operates several family tree farms that produce timber for lumber and paper. He volunteers as a medication trainer and consultant pharmacist at Pleasant Hills Children’s Home.
Vance is a graduate of the University of Texas at Austin College of Pharmacy.
Pam Randhawa, MPM
Advisor
Pam Randhawa is CEO and Founder of Empiriko, an early-stage biotech company focused on developing antiviral therapeutics and home/clinic-based point-of-care diagnostics for personalized patient treatment and monitoring. Pam has over 20 years of leadership experience in the healthcare/life sciences industries. Prior to founding Empiriko, she co-founded AgroGreen Biofuels, an alternative biofuels technology company using agriculture waste.
Pam serves on the Board of Directors of the Massachusetts Life Sciences Center (MLSC), a state investment agency responsible for $1.6 billion fund to support life sciences innovation. She is the Chair of the Board of Directors of the Massachusetts Biotechnology Council. Pam also serves on the Board of Directors of Hercules Capital with $15 billion under management.
Pam has served on several boards and councils, including the World Economic Forum’s Global Future Council on Biotechnology; the NSF/NIJ Industrial Advisory Board of Center for Advanced Research in Forensic Science chair; the NIH review panel for SBIR/STTR Commercialization Readiness Pilot Program, the Economic Development Planning Council for the State of MA and the Women’s Workforce Council to eliminate the gender wage gap. She serves as a judge for the Harvard Business School’s New Venture Competition. Pam holds a bachelor’s degree in economics from the University of Rajasthan, India, and earned a master’s degree from the Heinz School of Public Policy and Management at Carnegie-Mellon University.
Ronald Kuppersmith, M.D., MBA
Advisor
Ron is the CEO and co-founder of ENT Specialty Partners, a multi-site and full-service private practice in Texas. He is a proven leader within the specialty, having served as the President of the American Academy of Otolaryngology-Head and Neck Surgery, President of the Texas Association of Otolaryngology, and as a Professor of Surgery at the Texas A&M Health Science Center College of Medicine.
Ron has extensive experience working closely with management of health service, medical device and pharmaceutical companies, non-profit organizations, and investors in a variety of capacities including board member, founder, investor, advisor and in operational roles. Ron is the Chief Medical Advisor for Cyrano Therapeutics, a former board member of Spirox (acquired by Entellus), former board advisor of Entellus (acquired by Stryker), and a former board member of Arrinex (acquired by Stryker).
Ron trained in Otolaryngology-Head and Neck Surgery at Baylor College of Medicine in Houston. He has a BA in Economics and MD from the University of Michigan and an MBA from University of Washington.
Ronald Kuppersmith, M.D., MBA
Advisor
Ron is the CEO and co-founder of ENT Specialty Partners, a multi-site and full-service private practice in Texas. He is a proven leader within the specialty, having served as the President of the American Academy of Otolaryngology-Head and Neck Surgery, President of the Texas Association of Otolaryngology, and as a Professor of Surgery at the Texas A&M Health Science Center College of Medicine.
Ron has extensive experience working closely with management of health service, medical device and pharmaceutical companies, non-profit organizations, and investors in a variety of capacities including board member, founder, investor, advisor and in operational roles. Ron is the Chief Medical Advisor for Cyrano Therapeutics, a former board member of Spirox (acquired by Entellus), former board advisor of Entellus (acquired by Stryker), and a former board member of Arrinex (acquired by Stryker).
Ron trained in Otolaryngology-Head and Neck Surgery at Baylor College of Medicine in Houston. He has a BA in Economics and MD from the University of Michigan and an MBA from University of Washington.
Matthew Branch, M.D.
Chief Executive Officer & Co-founder
Matthew Branch, M.D. is a board-certified otolaryngologist-head and neck surgeon. He has a private practice in Waxahachie, Texas. Matt is an active member of the American Academy of Otolaryngology-Head and Neck Surgery and the Texas Medical Association.
Matt has also published scientific papers, book chapters, and professional presentations in the areas of otology, skull-base surgery, head and neck cancer surgery, and wound healing. As a general otolaryngologist serving nine counties, he leveraged 18 years of clinical expertise to develop a technology that expedites the treatment of otitis externa. Matt co- founded ENTRx in 2011.
Originally from Texas, Matt attended the University of Texas HSC Medical School in Houston, Texas. Matt is a graduate of the University of Pittsburgh Medical Center’s prestigious otolaryngology residency program.
Vance Oglesbee, RPh.
Chief Operating Officer & Co-founder
Vance is a formulation pharmacist and an entrepreneur in the prescription compounding space. As CEO of Hometown Pharmacy, Vance owns and operates three pharmacies in Texas.
Over the years, he has advised on pharmacy chain management and the purchase and sale of pharmacies. Vance is a current director and past Chairman of American Pharmacies, a large national independent pharmacy cooperative.
Vance leveraged his background in prescription compounding to develop a proprietary technology to expedite the treatment of otitis externa. Vance co-founded ENTRx in 2011.
He currently serves as Vice President of the Freestone Medical Center Board of Directors. Vance also co-owns and operates several family tree farms that produce timber for lumber and paper. He volunteers as a medication trainer and consultant pharmacist at Pleasant Hills Children’s Home.
Vance is a graduate of the University of Texas at Austin College of Pharmacy.
Tamar Shay Tannas, AB
Vice President of Business Development
Tamar Shay Tannas is an entrepreneur. As founder and CEO of BabyBriefcase, she invented, developed, manufactured, and launched a new consumer product category to the highly saturated baby market. Tamar defined the marketing and branding that generated national press coverage in the Boston Globe, Pregnancy Magazine (The A List), people.com, and local TV spots. She managed operations including product design and testing, contract manufacturing, quality control, 3rd party warehousing, and customer service. Since she successfully exited the business, BabyBriefcase continues to thrive in over 400 stores including all of Nordstrom’s locations.
Prior to BabyBriefcase, Tamar held senior business development positions in business intelligence technology and services companies. She generated millions selling to large corporations including EMC. She was a guest speaker at the Harvard Business School on business-to-business sales tactics.
Based in Dallas, Tamar coaches pro bono first generation students in college essay, résumé, and interview strategies. She is conversant in Mandarin, Russian, Hebrew, Spanish, Cantonese and French. Tamar graduated cum laude from Harvard College with an A.B. in Social Studies.
Pam Randhawa, MPM
Advisor
Pam Randhawa is CEO and Founder of Empiriko, an early-stage biotech company focused on developing antiviral therapeutics and home/clinic-based point-of-care diagnostics for personalized patient treatment and monitoring. Pam has over 20 years of leadership experience in the healthcare/life sciences industries. Prior to founding Empiriko, she co-founded AgroGreen Biofuels, an alternative biofuels technology company using agriculture waste.
Pam serves on the Board of Directors of the Massachusetts Life Sciences Center (MLSC), a state investment agency responsible for $1.6 billion fund to support life sciences innovation. She is the Chair of the Board of Directors of the Massachusetts Biotechnology Council. Pam also serves on the Board of Directors of Hercules Capital with $15 billion under management.
Pam has served on several boards and councils, including the World Economic Forum’s Global Future Council on Biotechnology; the NSF/NIJ Industrial Advisory Board of Center for Advanced Research in Forensic Science chair; the NIH review panel for SBIR/STTR Commercialization Readiness Pilot Program, the Economic Development Planning Council for the State of MA and the Women’s Workforce Council to eliminate the gender wage gap. She serves as a judge for the Harvard Business School’s New Venture Competition. Pam holds a bachelor’s degree in economics from the University of Rajasthan, India, and earned a master’s degree from the Heinz School of Public Policy and Management at Carnegie-Mellon University.
Ronald Kuppersmith, M.D., MBA
Advisor
Ron is the CEO and co-founder of ENT Specialty Partners, a multi-site and full-service private practice in Texas. He is a proven leader within the specialty, having served as the President of the American Academy of Otolaryngology-Head and Neck Surgery, President of the Texas Association of Otolaryngology, and as a Professor of Surgery at the Texas A&M Health Science Center College of Medicine.
Ron has extensive experience working closely with management of health service, medical device and pharmaceutical companies, non-profit organizations, and investors in a variety of capacities including board member, founder, investor, advisor and in operational roles. Ron is the Chief Medical Advisor for Cyrano Therapeutics, a former board member of Spirox (acquired by Entellus), former board advisor of Entellus (acquired by Stryker), and a former board member of Arrinex (acquired by Stryker).
Ron trained in Otolaryngology-Head and Neck Surgery at Baylor College of Medicine in Houston. He has a BA in Economics and MD from the University of Michigan and an MBA from University of Washington.
Matthew Branch, M.D.
Chief Executive Officer & Co-founder
Matthew Branch, M.D. is a board-certified otolaryngologist-head and neck surgeon. He has a private practice in Waxahachie, Texas. Matt is an active member of the American Academy of Otolaryngology-Head and Neck Surgery and the Texas Medical Association.
Matt has also published scientific papers, book chapters, and professional presentations in the areas of otology, skull-base surgery, head and neck cancer surgery, and wound healing. As a general otolaryngologist serving nine counties, he leveraged 18 years of clinical expertise to develop a technology that expedites the treatment of otitis externa. Matt co- founded ENTRx in 2011.
Originally from Texas, Matt attended the University of Texas HSC Medical School in Houston, Texas. Matt is a graduate of the University of Pittsburgh Medical Center’s prestigious otolaryngology residency program.
ENT401 is a viscous, hydrophobic carrier for a wide variety of APIs, allowing exposure and easy absorption across any epithelial or mucosal surface.
The elegant nature of the ENT401 vehicle is in its minimalist design. This approach avoids the retention of excipients common in other products designed for use on the skin. These products routinely desiccate and adhere, necessitating multiple in-office painful debridements.
OUR PLATFORM
Our technology is based on four elements:
Suspend the APIs in a viscous carrier
Distribute them throughout the treatment area for wide exposure and absorption
Create a hydrophobic environment that inhibits the survival of bacteria or fungus
Remove barriers to API exposure by dissolving and dislodging persistent cerumen or dry skin
Application Opportunities Beyond ENT401
Otorhinolaryngology
Sinusitis
Genitourinary
Cystitis, urethritis, ureteritis
Ophthalmology
Blepharitis, conjunctivitis
Wound care
OB-GYN
Vaginitis, cervicitis
OUR SOLUTION: ENT401
With ENT401, all otitis externa can be treated whether bacterial or fungal. ENT401 will be the first FDA-approved single dose treatment for otitis externa with time-tested antibacterial, antifungal, and anti-inflammatory APIs to treat pain, itch, and swelling.
The current seven-day course of drops often fails. In comparison, ENT401 is a single dose treatment for otitis externa of bacterial or fungal origin, administered by a health care provider with relief of symptoms within 2-3 days and less than 1% persistent disease.
NEW SINGLE-DOSE FORMULATION
A proprietary, viscous suspension that delivers 3 FDA-approved APIs
OUR PIPELINE
SEE ENT401 IN ACTION
BEFORE TREATMENT
AFTER TREATMENT (7 DAYS)
